When was Senisca founded?

Senisca was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Senisca located?

Senisca is headquartered in Exeter, United Kingdom.

Which legal entities is Senisca associated with?

Senisca is associated with Senisca Ltd.

How many employees does Senisca have?

As of Jun 30, 2026, the latest employee count at Senisca is 15.

Is Senisca a funded company?

Senisca is a funded company, having raised a total of $9.03M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Mar 12, 2021.

When was the latest funding round of Senisca?

Senisca's latest funding was a $***** Series A round on Mar 18, 2024, with participation from 6 investors.

Where does Senisca rank among its competitors?

Senisca ranks 200th amongst 557 active competitors, of which 204 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Senisca?

Senisca's top competitors include Alnylam, Spark Therapeutics and Moderna. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Senisca - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of senotherapeutics that targets the diseases and signs of ageing. The company develops a new generation of oligonucleotide-based therapies that helps in reversing the aging of old cells and tissues through modulation of RNA splicing. This helps in the restoration of splicing factor levels and reverse senescence.

Website: www.senisca.com/
Social
Email ID: *****@senisca.com
Phone Number: +44 **********

Key Metrics

Founded Year

2020

Location

Exeter, United Kingdom

Stage

Series A

Total Funding

$9.03M in 5 rounds

Latest Funding Round

Series A, Mar 18, 2024, $*****

Investors

R42 Group & 26 more

Ranked

200^th among 557 active competitors

Employee Count

15 as on Jun 30, 2026

Similar Companies

Alnylam & 696 more

View Senisca's full profile

Senisca is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Senisca Ltd CIN: 12948837 , United Kingdom, Active	Oct 12, 2020	-	18 (As on Dec 31, 2024)

Senisca has raised a total funding of $9.03M over 5 rounds. Its first funding round was on Mar 12, 2021. Its latest funding round was a Series A round on Mar 18, 2024 for $*****. 6 investors participated in its latest round. Senisca has 16 institutional investors and 11 angel investors.

Here is the list of recent funding rounds of Senisca:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 18, 2024	6025287	Series A	7165263	5343031	3259738	1415981
Apr 20, 2023	6213964	Grant (prize money)	1443924	7344985	6397659	Gov
Jun 10, 2022	2901562	Seed	4834120	9774921	R42 Group	Emerging Longevity Ventures & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Senisca's funding rounds and investors

The founders of Senisca are Kirsty Semple, Ben Lee and Lorna Harries.

Here are the details of Senisca's key team members:

Kirsty Semple: Co-Founder & CEO of Senisca.
Contact Info: 1 email address
Ben Lee: Co-Founder & CTO of Senisca.
Contact Info: 1 email address
Lorna Harries: Co-Founder & CSO of Senisca.
Contact Info: 1 email address

View details of Senisca's Founder profiles and Board Members

Senisca's employee count trend

Senisca has 15 employees as of Jun 26. Here is Senisca's employee count trend over the years:

Uncover Senisca's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Senisca include Alnylam, Spark Therapeutics and Moderna. Here is the list of Top 10 competitors of Senisca, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
4th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, MassChallenge & 19 others	70/100
5th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
7th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
8th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Healthcap & 10 others	69/100
9th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
10th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, Invus & 16 others	68/100
200th	Senisca 2020, Exeter (United Kingdom), Series A	Developer of senotherapeutics that targets the diseases and signs of ageing	$9.03M	APEX Ventures, R42 Group & 25 others	42/100